How were (NVET)'s earnings last quarter?

(NVET) (NASDAQ:NVET) announced its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.

(NVET) (NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

What other stocks do shareholders of (NVET) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (NVET) investors own include Frontline (FRO) , Achillion Pharmaceuticals (ACHN) , Anthera Pharmaceuticals (ANTH) , Sphere 3D (ANY) , Arena Pharmaceuticals (ARNA) , Yamana Gold (AUY) and BioLineRx (BLRX) .

NASDAQ:NVET

(NVET) (NVET) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $6.72
▼
$6.72
50-Day Range: N/A
52-Week Range: $2.75
▼
$6.76

Volume: N/A
Average Volume: 38,104 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (NVET) alerts:

Ad Paradigm Press

Musk’s new company could top a trillion?

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

About (NVET) Stock (NASDAQ:NVET)

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company’s advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Ad Paradigm Press

Musk’s new company could top a trillion?

The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.

Click here to see the details because there’s not much time to prepare.

NVET Stock News Headlines

April 23, 2024 | msn.com

Mavericks' forgotten bench player is missing piece in playoff puzzle

January 16, 2023 | msn.com

‘A man who understands Hong Kong’: Beijing’s new liaison office head vows to bridge communication between city and central authorities

September 13, 2024 | Porter & Company (Ad)

Trump’s weapon lurks in abandoned America

Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…

December 30, 2022 | msn.com

Prescott has 2 TD passes, Cowboys top banged-up Titans 27-13

October 10, 2022 | msn.com

Selena Gomez Talks Mental Health in ‘My Mind and Me’ Trailer

September 29, 2022 | msn.com

COVID in California: Boston sees a ‘worrisome’ virus spike in wastewater

August 18, 2022 | msn.com

"There was a lot of screaming, it was terrifying": City centre workers' fears as man stabbed outside Mile Castle pub in Newcastle

July 1, 2022 | thestreet.com

Nymox Pharmaceutical Corporation News

See More Headlines

Receive NVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (NVET) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/11/2017
Today: 9/13/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:NVET
CUSIP: N/A
CIK: 1618561
Web: www.nexvet.com
Phone: +353-1-2158100
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

NVET Stock Analysis - Frequently Asked Questions

How were (NVET)'s earnings last quarter?: (NVET) (NASDAQ:NVET) announced its quarterly earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02.
When did (NVET) IPO?: (NVET) (NVET) raised $58 million in an IPO on Thursday, February 5th 2015. The company issued 4,000,000 shares at $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.
What other stocks do shareholders of (NVET) own?: Based on aggregate information from My MarketBeat watchlists, some other companies that (NVET) investors own include Frontline (FRO), Achillion Pharmaceuticals (ACHN), Anthera Pharmaceuticals (ANTH), Sphere 3D (ANY), Arena Pharmaceuticals (ARNA), Yamana Gold (AUY) and BioLineRx (BLRX).